Subsequent development of theranostic agents for infection/inflammation (Velikyan 2018), prostate cancer (Eder et al. 2014; Lenzo et al. 2018; Ruangma et al. 2018), C-X-C chemokine receptor type 4 (CXCR4) (Gourni et al. 2011; Herrmann et al. 2016) and, most recently, fibroblast activation protein inhibitors (FAPI) (Kratochwil et al. 2019) is further driving demand and highlights the need for access to a reliable (and economical) supply of 68Ga8 that is the focus of this paper. Here, CXCR4 is linked to infection.